Skip to main content
SpringerLink
Log in

Prebiotics, Probiotics, and Dietary Supplements

  • Chapter
  • First Online:
Nutrition, Weight, and Digestive Health

  • 742 Accesses

Abstract

Prebiotics are selectively fermented substrates that are utilized by host microorganisms and allow specific changes to the gastrointestinal microbiota that confer potential health benefits. Probiotics are live organisms which, when taken enterally, may confer a health benefit to the host. Dietary supplements are over-the-counter products taken orally that contain dietary ingredients such as vitamins, minerals, amino acids, herbs, botanicals, or other substances whose use to promote heath or treat illness does not require medical supervision. Dietary supplements that have been studied for their possible role in gastrointestinal conditions include peppermint, ginger, and licorice, among others. Medical foods, which are foods formulated to be consumed under the supervision of a physician and intended for the dietary management of an illness, have also been studied for their potential role in gastrointestinal disease. This chapter summarizes available data regarding the role of prebiotics, probiotics, dietary supplements, and medical foods in gastrointestinal disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Sanders ME, Merenstein DJ, Reid G, Gibson GR, Rastall RA. Probiotics and prebiotics in intestinal health and disease: from biology to the clinic. Nat Rev Gastroenterol Hepatol. 2019:1–12.

    Google Scholar 

  2. Ford AC, Moayyedi P, Chey WD, Harris LA, Lacy BE, Saito YA, Quigley EM. American College of Gastroenterology monograph on management of irritable bowel syndrome. Am J Gastroenterol. 2018;113:1–18.

    Article  PubMed  Google Scholar 

  3. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr. 1995;125(6):1401–12.

    Article  CAS  PubMed  Google Scholar 

  4. Gibson GR, Scott KP, Rastall RA, Tuohy KM, Hotchkiss A, Dubert-Ferrandon A, Gareau M, Murphy EF, Saulnier D, Loh G, Macfarlane S. Dietary prebiotics: current status and new definition. Food Sci Technol Bull Funct Foods. 2010;7(1):1–19.

    Article  Google Scholar 

  5. Gibson GR, Hutkins R, Sanders ME, Prescott SL, Reimer RA, Salminen SJ, Scott K, Stanton C, Swanson KS, Cani PD, Verbeke K. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol. 2017;14(8):491.

    Article  PubMed  Google Scholar 

  6. Guarner F, Khan AG, Garisch J, Eliakim R, Gangl A, Thomson A, Krabshuis J, Lemair T, Kaufmann P, De Paula JA, Fedorak R. World gastroenterology organisation global guidelines: probiotics and prebiotics october 2011. J Clin Gastroenterol. 2012;46(6):468–81.

    Article  PubMed  Google Scholar 

  7. Quigley EM. Prebiotics and probiotics: their role in the management of gastrointestinal disorders in adults. Nutr Clin Pract. 2012;27(2):195–200.

    Article  PubMed  Google Scholar 

  8. Holscher HD. Dietary fiber and prebiotics and the gastrointestinal microbiota. Gut Microbes. 2017;8(2):172–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Bindels LB, Delzenne NM, Cani PD, Walter J. Towards a more comprehensive concept for prebiotics. Nat Rev Gastroenterol Hepatol. 2015;12(5):303.

    Article  CAS  PubMed  Google Scholar 

  10. Trop TK. Intestinal microbiota, probiotics and prebiotics in inflammatory bowel disease. World J Gastroenterol: WJG. 2014;20(33):11505.

    Article  Google Scholar 

  11. Lambert JE, Parnell JA, Eksteen B, Raman M, Bomhof MR, Rioux KP, Madsen KL, Reimer RA. Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol. BMC Gastroenterol. 2015;15(1):169.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Serban DE. Gastrointestinal cancers: influence of gut microbiota, probiotics and prebiotics. Cancer Lett. 2014;345(2):258–70.

    Article  CAS  PubMed  Google Scholar 

  13. Alexea O, Bacarea V, Piqué N. The combination of oligo-and polysaccharides and reticulated protein for the control of symptoms in patients with irritable bowel syndrome: Results of a randomised, placebo-controlled, double-blind, parallel group, multicentre clinical trial. United European Gastroenterol J. 2016;4(3):455–65.

    Article  CAS  PubMed  Google Scholar 

  14. Huaman JW, Mego M, Manichanh C, Cañellas N, Cañueto D, Segurola H, Jansana M, Malagelada C, Accarino A, Vulevic J, Tzortzis G. Effects of prebiotics vs a diet low in FODMAPs in patients with functional gut disorders. Gastroenterology. 2018;155(4):1004–7.

    Article  CAS  PubMed  Google Scholar 

  15. Wilson B, Rossi M, Dimidi E, Whelan K. Prebiotics in irritable bowel syndrome and other functional bowel disorders in adults: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr. 2019;109(4):1098–111.

    Article  PubMed  Google Scholar 

  16. Cummings JH, Branch W, Jenkins DJA, Southgate DAT, Houston H, James WPT. Colonic response to dietary fibre from carrot, cabbage, apple, bran, and guar gum. The Lancet. 1978;311(8054):5–9.

    Article  Google Scholar 

  17. Ford AC, Quigley EM, Lacy BE, Lembo AJ, Saito YA, Schiller LR, Soffer EE, Spiegel BM, Moayyedi P. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol. 2014;109(10):1547–61.

    Article  PubMed  Google Scholar 

  18. Waitzberg DL, Pereira CC, Logullo L, Jacintho TM, Almeida D. Microbiota benefits after inulin and partially hydrolyzed guar gum supplementation-a randomized clinical trial in constipated women. Nutr Hosp. 2012;27(1):123–9.

    CAS  Google Scholar 

  19. Wilson B, Whelan K. Prebiotic inulin-type fructans and galacto-oligosaccharides: definition, specificity, function, and application in gastrointestinal disorders. J Gastroenterol Hepatol. 2017;32:64–8.

    Article  CAS  PubMed  Google Scholar 

  20. Lindsay JO, Whelan K, Stagg AJ, Gobin P, Al-Hassi HO, Rayment N, Kamm MA, Knight SC, Forbes A. Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn’s disease. Gut. 2006;55(3):348–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Benjamin JL, Hedin CR, Koutsoumpas A, Ng SC, McCarthy NE, Hart AL, Kamm MA, Sanderson JD, Knight SC, Forbes A, Stagg AJ. Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn’s disease. Gut. 2011;60(7):923–9.

    Article  CAS  PubMed  Google Scholar 

  22. Joossens M, De Preter V, Ballet V, Verbeke K, Rutgeerts P, Vermeire S. Effect of oligofructose-enriched inulin (OF-IN) on bacterial composition and disease activity of patients with Crohn’s disease: results from a double-blinded randomised controlled trial. Gut. 2012;61(6):958.

    Article  PubMed  Google Scholar 

  23. Fernandez-Banares F, Hinojosa J, Sanchez-Lombrana JL, Navarro E, Martınez-Salmerón JF, Garcıa-Pugés A, Gonzalez-Huix F, Riera J, Gonzalez-Lara V, Domınguez-Abascal F, Gine JJ. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Am J Gastroenterol. 1999;94(2):427–33.

    Article  CAS  PubMed  Google Scholar 

  24. Furrie E, Macfarlane S, Kennedy A, Cummings JH, Walsh SV, O’neil DA, Macfarlane GT. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut. 2005;54(2):242–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Lilly DM, Stillwell RH. Probiotics: growth-promoting factors produced by microorganisms. Science. 1965;147(3659):747–8.

    Article  CAS  PubMed  Google Scholar 

  26. Quigley EM. Prebiotics and probiotics in digestive health. Clin Gastroenterol Hepatol. 2019;17(2):333–44.

    Article  CAS  PubMed  Google Scholar 

  27. Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, Calder PC. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatosl. 2014;11(8):506–14.

    Article  Google Scholar 

  28. Guarner, F., Sanders, M.E. and Eliakim, R., World Gastroenterology Organization. World gastroenterology organisation global guidelines: probiotics and prebiotics. February 2017.

    Google Scholar 

  29. Wilkins T, Sequoia J. Probiotics for gastrointestinal conditions: a summary of the evidence. Am Fam Physician. 2017;96(3):170–8.

    PubMed  Google Scholar 

  30. Park J, Floch MH. Prebiotics, probiotics, and dietary fiber in gastrointestinal disease. Gastroenterol Clin North Am. 2007;36(1):47–63.

    Article  PubMed  Google Scholar 

  31. Pittayanon R, Lau JT, Leontiadis GI, Tse F, Yuan Y, Surette M, Moayyedi P. Differences in gut microbiota in patients with vs without inflammatory bowel diseases: a systematic review. Gastroenterology. 2020;158(4):930–46.

    Article  PubMed  Google Scholar 

  32. Cheifetz AS, Gianotti R, Luber R, Gibson PR. Complementary and alternative medicines used by patients with inflammatory bowel. Gastroenterology. 2017;152(2):415–429.e15.

    Article  PubMed  Google Scholar 

  33. Abraham BP, Quigley EM. Probiotics in inflammatory bowel disease. Gastroenterology Clin. 2017;46(4):769–82.

    Article  Google Scholar 

  34. Koretz RL. Probiotics in gastroenterology: how pro is the evidence in adults? Am J Gastroenterol. 2018;113(7):1125–36.

    Article  PubMed  Google Scholar 

  35. Tursi A, Brandimarte G, Papa A, Giglio A, Elisei W, Giorgetti GM, Forti G, Morini S, Hassan C, Pistoia MA, Modeo ME. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL# 3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2010;105(10):2218.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A. Effect of a probiotic preparation (VSL# 3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol. 2009;104(2):437–43.

    Article  CAS  PubMed  Google Scholar 

  37. Singh S, Feuerstein JD, Binion DG, Tremaine WJ. AGA technical review on the management of mild-to-moderate ulcerative colitis. Gastroenterology. 2019;156(3):769–808.

    Article  PubMed  Google Scholar 

  38. Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, Vitali B, Poggioli G, Miglioli M, Campieri M. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology. 2003;124(5):1202–9.

    Article  PubMed  Google Scholar 

  39. Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, Nicholls RJ, Gionchetti P, Campieri M, Kamm MA. Once daily high dose probiotic therapy (VSL# 3) for maintaining remission in recurrent or refractory pouchitis. Gut. 2004;53(1):108–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, Poggioli G, Miglioli M, Campieri M. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119(2):305–9.

    Article  CAS  PubMed  Google Scholar 

  41. Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut. 2002;51(3):405–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Regueiro M, Velayos F, Greer JB, Bougatsos C, Chou R, Sultan S, Singh S. American Gastroenterological Association Institute technical review on the management of Crohn’s disease after surgical resection. Gastroenterology. 2017;152(1):277–95.

    Article  PubMed  Google Scholar 

  43. Marteau P, Lémann M, Seksik P, Laharie D, Colombel JF, Bouhnik Y, Cadiot G, Soulé JC, Bourreille A, Metman E, Lerebours E. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn’s disease: a randomised, double blind, placebo controlled GETAID trial. Gut. 2006;55(6):842–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Fedorak RN, Feagan BG, Hotte N, Leddin D, Dieleman LA, Petrunia DM, Enns R, Bitton A, Chiba N, Paré P, Rostom A. The probiotic VSL# 3 has anti-inflammatory effects and could reduce endoscopic recurrence after surgery for Crohn's disease. Clin Gastroenterol Hepatol. 2015;13(5):928–35.

    Article  CAS  PubMed  Google Scholar 

  45. Van Gossum A, Dewit O, Louis E, de Hertogh G, Baert F, Fontaine F, DeVos M, Enslen M, Paintin M, Franchimont D. Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after ileo-caecal resection. Inflamm Bowel Dis. 2007;13(2):135–42.

    Article  PubMed  Google Scholar 

  46. Zhong C, Qu C, Wang B, Liang S, Zeng B. Probiotics for preventing and treating small intestinal bacterial overgrowth. J Clin Gastroenterol. 2017;51(4):300–11.

    Article  CAS  PubMed  Google Scholar 

  47. Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol. 2009;104(4):1033–49.

    Article  CAS  PubMed  Google Scholar 

  48. O’Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O’Sullivan GC, Kiely B, Collins JK, Shanahan F, Quigley EM. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128(3):541–51.

    Article  PubMed  Google Scholar 

  49. Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O'mahony, L., Kiely, B., Shanahan, F. and Quigley, E.M. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006;101(7):1581–90.

    Article  PubMed  Google Scholar 

  50. Ringel-Kulka T, McRorie J, Ringel Y. Multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the benefit of the probiotic Bifidobacterium infantis 35624 in non-patients with symptoms of abdominal discomfort and bloating. Am J Gastroenterol. 2017;112(1):145–51.

    Article  PubMed  Google Scholar 

  51. Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein AE, Brandt LJ, Quigley EM. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut. 2010;59(3):325–32.

    Article  CAS  PubMed  Google Scholar 

  52. McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol: WJG. 2008;14(17):2650.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Hoveyda N, Heneghan C, Mahtani KR, Perera R, Roberts N, Glasziou P. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol. 2009;9(1):15.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Whelan K, Quigley EM. Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease. Curr Opin Gastroenterol. 2013;29(2):184–9.

    Article  PubMed  Google Scholar 

  55. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol. 2006;101(4):812–22.

    Article  PubMed  Google Scholar 

  56. Johnston BC, Goldenberg JZ, Vandvik PO, Sun X, Guyatt GH. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2011;9(11):CD004827.

    Google Scholar 

  57. Goldenberg JZ, Yap C, Lytvyn L, Lo CKF, Beardsley J, Mertz D, Johnston BC. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2017;12(12):CD006095.

    PubMed  Google Scholar 

  58. Hempel S, Newberry SJ, Maher AR, Wang Z, Miles JN, Shanman R, Johnsen B, Shekelle PG. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA. 2012;307(18):1959–69.

    Article  CAS  PubMed  Google Scholar 

  59. Allen SJ, Wareham K, Wang D, Bradley C, Hutchings H, Harris W, Dhar A, Brown H, Foden A, Gravenor MB, Mack D. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet. 2013;382(9900):1249–57.

    Article  Google Scholar 

  60. Shen NT, Maw A, Tmanova LL, Pino A, Ancy K, Crawford CV, Simon MS, Evans AT. Timely use of probiotics in hospitalized adults prevents Clostridium difficile infection: a systematic review with meta-regression analysis. Gastroenterology. 2017;152(8):1889–900.

    Article  PubMed  Google Scholar 

  61. McGee RG, Bakens A, Wiley K, Riordan SM, Webster AC. Probiotics for patients with hepatic encephalopathy. Cochrane Database Syst Rev. 2011;9(11):CD008716.

    Google Scholar 

  62. Bajaj JS, Saeian K, Christensen KM, Hafeezullah M, Varma RR, Franco J, Pleuss JA, Krakower G, Hoffmann RG, Binion DG. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am J Gastroenterol. 2008;103(7):1707–15.

    Article  PubMed  Google Scholar 

  63. Agrawal A, Sharma BC, Sharma P, Sarin SK. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy. Am J Gastroenterol. 2012;107(7):1043–50.

    Article  CAS  PubMed  Google Scholar 

  64. Dhiman RK, Rana B, Agrawal S, Garg A, Chopra M, Thumburu KK, Khattri A, Malhotra S, Duseja A, Chawla YK. Probiotic VSL# 3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial. Gastroenterology. 2014;147(6):1327–37.

    Article  CAS  PubMed  Google Scholar 

  65. Marchesi JR, Adams DH, Fava F, Hermes GD, Hirschfield GM, Hold G, Quraishi MN, Kinross J, Smidt H, Tuohy KM, Thomas LV. The gut microbiota and host health: a new clinical frontier. Gut. 2016;65(2):330–9.

    Article  PubMed  Google Scholar 

  66. Pala V, Sieri S, Berrino F, Vineis P, Sacerdote C, Palli D, Masala G, Panico S, Mattiello A, Tumino R, Giurdanella MC. Yogurt consumption and risk of colorectal cancer in the Italian European prospective investigation into cancer and nutrition cohort. Int J Cancer. 2011;129(11):2712–9.

    Article  CAS  PubMed  Google Scholar 

  67. De Simone C. The unregulated probiotic market. Clin Gastroenterol Hepatol. 2019;17(5):809–17.

    Article  PubMed  Google Scholar 

  68. US Food and Drug Administration. FDA 101: dietary supplements. FDA Consumer Health. Inf Dent. 4. 2008. https://www.fda.gov/consumers/consumer-updates/fda-101-dietary-supplements.

  69. Ciampa BP, Ramos ER, Borum M, Doman DB. The emerging therapeutic role of medical foods for gastrointestinal disorders. Gastroenterol Hepatol. 2017;13(2):104. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5402682/

    Google Scholar 

  70. Kantor ED, Rehm CD, Du M, White E, Giovannucci EL. Trends in dietary supplement use among US adults from 1999-2012. JAMA. 2016;316(14):1464–74. https://jamanetwork.com/journals/jama/article-abstract/2565748

    Article  PubMed  PubMed Central  Google Scholar 

  71. Bloomberg: https://www.bloomberg.com/press-releases/2019-12-04/dietary-supplements-market-to-reach-usd-216-3-billion-by-2026-reports-and-data

  72. Bailey RL, Gahche JJ, Miller PE, Thomas PR, Dwyer JT. Why US adults use dietary supplements. JAMA Intern Med. 2013;173(5):355–61. https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/1568520

    Article  CAS  PubMed  Google Scholar 

  73. Swann JP. The history of efforts to regulate dietary supplements in the USA. Drug Test Anal. 2016;8(3-4):271–82. https://onlinelibrary.wiley.com/doi/full/10.1002/dta.1919

    Article  CAS  PubMed  Google Scholar 

  74. Hutt PB. FDA statutory authority to regulate the safety of dietary supplements. Am J Law Med. 2005;31(2-3):155–74. https://journals.sagepub.com/doi/abs/10.1177/009885880503100202?journalCode=jlma

    Article  PubMed  Google Scholar 

  75. Denham BE. Dietary supplements—regulatory issues and implications for public health. JAMA. 2011;306(4):428–9. https://jamanetwork.com/journals/jama/article-abstract/1104131

    Article  CAS  PubMed  Google Scholar 

  76. Cohen PA. Assessing supplement safety—the FDA’s controversial proposal. N Engl J Med. 2012;366(5):389–91. https://www.nejm.org/doi/full/10.1056/NEJMp1113325

    Article  CAS  PubMed  Google Scholar 

  77. Ziker D. What lies beneath: an examination of the underpinnings of dietary supplement safety regulation. Am J Law Med. 2005;31(2-3):269–84. https://journals.sagepub.com/doi/abs/10.1177/009885880503100205?journalCode=jlma

    Article  PubMed  Google Scholar 

  78. Ashar BH, Rice TN, Sisson SD. Physicians' understanding of the regulation of dietary supplements. Arch Intern Med. 2007;167(9):966–9. https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/412433

    Article  PubMed  Google Scholar 

  79. Geller AI, Shehab N, Weidle NJ, Lovegrove MC, Wolpert BJ, Timbo BB, Mozersky RP, Budnitz DS. Emergency department visits for adverse events related to dietary supplements. N Engl J Med. 2015;373(16):1531–40. https://www.nejm.org/doi/full/10.1056/nejmsa1504267

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Harel Z, Harel S, Wald R, Mamdani M, Bell CM. The frequency and characteristics of dietary supplement recalls in the United States. JAMA Intern Med. 2013;173(10):929–30. https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/1678813

    Article  Google Scholar 

  81. Hills JM, Aaronson PI. The mechanism of action of peppermint oil on gastrointestinal smooth muscle: an analysis using patch clamp electrophysiology and isolated tissue pharmacology in rabbit and guinea pig. Gastroenterology. 1991;101(1):55–65.

    Article  CAS  PubMed  Google Scholar 

  82. Pittler MH, Ernst E. Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis. Am J Gastroenterol. 1998;93(7):1131–5.

    Article  CAS  PubMed  Google Scholar 

  83. Liu JH, Chen GH, Yeh HZ, Huang CK, Poon SK. Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial. J Gastroenterol. 1997;32(6):765.

    Article  CAS  PubMed  Google Scholar 

  84. Alam MS, Roy PK, Miah AR, Mollick SH, Khan MR, Mahmud MC, Khatun S. Efficacy of Peppermint oil in diarrhea predominant IBS-a double blind randomized placebo-controlled study. Mymensingh Med J. 2013;22(1):27–30.

    CAS  PubMed  Google Scholar 

  85. Mann NS, Sandhu KS. Peppermint oil in irritable bowel syndrome: systematic evaluation of 1634 cases with meta-analysis. Intern Med J. 2012;19(1):5–6.

    Google Scholar 

  86. Ford AC, Talley NJ, Spiegel BM, Foxx-Orenstein AE, Schiller L, Quigley EM, Moayyedi P. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ. 2008;337:a2313.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Khanna R, MacDonald JK, Levesque BG. Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. J Clin Gastroenterol. 2014;48(6):505–12.

    Article  PubMed  Google Scholar 

  88. May B, Köhler S, Schneider B. Efficacy and tolerability of a fixed combination of peppermint oil and caraway oil in patients suffering from functional dyspepsia. Aliment Pharmacol Ther. 2000;14(12):1671–7.

    Article  CAS  PubMed  Google Scholar 

  89. Tate S. Peppermint oil: a treatment for postoperative nausea. J Adv Nurs. 1997;26(3):543–9.

    Article  CAS  PubMed  Google Scholar 

  90. Micklefield GH, Greving I, May B. Effects of peppermint oil and caraway oil on gastroduodenal motility. Phytother Res. 2000;14(1):20–3.

    Article  CAS  PubMed  Google Scholar 

  91. Hiki N, Kurosaka H, Tatsutomi Y, Shimoyama S, Tsuji E, Kojima J, Shimizu N, Ono H, Hirooka T, Noguchi C, Mafune KI. Peppermint oil reduces gastric spasm during upper endoscopy: a randomized, double-blind, double-dummy controlled trial. Gastrointest Endosc. 2003;57(4):475–82.

    Article  PubMed  Google Scholar 

  92. Yamamoto N, Nakai Y, Sasahira N, Hirano K, Tsujino T, Isayama H, Komatsu Y, Tada M, Yoshida H, Kawabe T, Hiki N. Efficacy of peppermint oil as an antispasmodic during endoscopic retrograde cholangiopancreatography. J Gastroenterol Hepatol. 2006;21(9):1394–8.

    PubMed  Google Scholar 

  93. Asao T, Kuwano H, Ide M, Hirayama I, Nakamura JI, Fujita KI, Horiuti R. Spasmolytic effect of peppermint oil in barium during double-contrast barium enema compared with Buscopan. Clin Radiol. 2003;58(4):301–5.

    Article  CAS  PubMed  Google Scholar 

  94. Sparks MJW, O'sullivan P, Herrington AA, Morcos SK. Does peppermint oil relieve spasm during barium enema? Br J Radiol. 1995;68(812):841–3.

    Article  CAS  PubMed  Google Scholar 

  95. Kligler B, Chaudary S. Peppermint oil. Am Fam Physician. 2007;75(7):1027–30.

    PubMed  Google Scholar 

  96. Nikkhah Bodagh M, Maleki I, Hekmatdoost A. Ginger in gastrointestinal disorders: a systematic review of clinical trials. Food Sci Nutr. 2019;7(1):96–108.

    Article  PubMed  Google Scholar 

  97. Ernst E, Pittler MH. Efficacy of ginger for nausea and vomiting: a systematic review of randomized clinical trials. Br J Anaesth. 2000;84(3):367–71.

    Article  CAS  PubMed  Google Scholar 

  98. Koretz RL, Rotblatt M. Complementary and alternative medicine in gastroenterology: the good, the bad, and the ugly. Clin Gastroenterol Hepatol. 2004;2(11):957–67.

    Article  PubMed  Google Scholar 

  99. Viljoen E, Visser J, Koen N, Musekiwa A. A systematic review and meta-analysis of the effect and safety of ginger in the treatment of pregnancy-associated nausea and vomiting. Nutr J. 2014;13(1):20.

    Article  PubMed  PubMed Central  Google Scholar 

  100. Thomson M, Corbin R, Leung L. Effects of ginger for nausea and vomiting in early pregnancy: a meta-analysis. J Am Board Fam Med. 2014;27(1):115–22.

    Article  PubMed  Google Scholar 

  101. Pace, J.C. Oral ingestion of encapsulated ginger and reported self-care actions for the relief of chemotherapy-associated nausea and vomiting. 1987.

    Google Scholar 

  102. Ryan JL, Heckler CE, Roscoe JA, Dakhil SR, Kirshner J, Flynn PJ, Hickok JT, Morrow GR. Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients. Support Care Cancer. 2012;20(7):1479–89.

    Article  PubMed  Google Scholar 

  103. Marx WM, Teleni L, McCarthy AL, Vitetta L, McKavanagh D, Thomson D, Isenring E. Ginger (Zingiber officinale) and chemotherapy-induced nausea and vomiting: a systematic literature review. Nutr Rev. 2013;71(4):245–54.

    Article  PubMed  Google Scholar 

  104. Bone ME, Wilkinson DJ, Young JR, McNeil J, Charlton S. Ginger root—a new antiemetic. The effect of ginger root on postoperative nausea and vomiting after major gynaecological surgery. Anaesthesia. 1990;45(8):669–71.

    Article  CAS  PubMed  Google Scholar 

  105. Phillips S, Ruggier R, Hutchinson SE. Zingiber officinale (ginger)–an antiemetic for day case surgery. Anaesthesia. 1993;48(8):715–7.

    Article  CAS  PubMed  Google Scholar 

  106. Arfeen Z, Owen H, Plummer JL, Ilsley AH, Sorby-Adams RAC, Doecke CJ. A double-blind randomized controlled trial of ginger for the prevention of postoperative nausea and vomiting. Anaesth Intensive Care. 1995;23(4):449–52.

    Article  CAS  PubMed  Google Scholar 

  107. Visalyaputra S, Petchpaisit N, Somcharoen K, Choavaratana R. The efficacy of ginger root in the prevention of postoperative nausea and vomiting after outpatient gynaecological laparoscopy. Anaesthesia. 1998;53(5):506–10.

    Article  CAS  PubMed  Google Scholar 

  108. Eberhart LH, Mayer R, Betz O, Tsolakidis S, Hilpert W, Morin AM, Geldner G, Wulf H, Seeling W. Ginger does not prevent postoperative nausea and vomiting after laparoscopic surgery. Anesth Anal. 2003;96(4):995–8.

    Article  Google Scholar 

  109. Kalava A, Darji SJ, Kalstein A, Yarmush JM, SchianodiCola J, Weinberg J. Efficacy of ginger on intraoperative and postoperative nausea and vomiting in elective cesarean section patients. Eur J Obstet Gynecol Reprod Biol. 2013;169(2):184–8.

    Article  CAS  PubMed  Google Scholar 

  110. Mandal P, Das A, Majumdar S, Bhattacharyya T, Mitra T, Kundu R. The efficacy of ginger added to ondansetron for preventing postoperative nausea and vomiting in ambulatory surgery. Pharm Res. 2014;6(1):52.

    Google Scholar 

  111. Montazeri AS, Hamidzadeh A, Raei M, Mohammadiun M, Montazeri AS, Mirshahi R, Rohani H. Evaluation of oral ginger efficacy against postoperative nausea and vomiting: a randomized, double-blinded clinical trial. Iran Red Crescent Med J. 2013;15(12):e12268.

    Article  PubMed  PubMed Central  Google Scholar 

  112. Zeraati H, Shahinfar J, Hesari SI, Masrorniya M, Nasimi F. The effect of ginger extract on the incidence and severity of nausea and vomiting after cesarean section under spinal anesthesia. Anesthesiol Pain Med. 2016;6(5):e38943.

    Article  Google Scholar 

  113. Seidi J, Ebnerasooli S, Shahsawari S, Nzarian S. The influence of oral ginger before operation on nausea and vomiting after cataract surgery under general anesthesia: a double-blind placebo-controlled randomized clinical trial. Electron Physician. 2017;9(1):3508.

    Article  PubMed  PubMed Central  Google Scholar 

  114. Rahimlou M, Yari Z, Hekmatdoost A, Alavian SM, Keshavarz SA. Ginger supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Hepat Mon. 2016;16(1):e34897.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  115. Hirata A, Funato H, Nakai M, Iizuka M, Abe N, Yagi Y, Shiraishi H, Jobu K, Yokota J, Hirose K, Hyodo M. Ginger orally disintegrating tablets to improve swallowing in older people. Biol Pharm Bull. 2016;39(7):1107–11.

    Article  CAS  PubMed  Google Scholar 

  116. Ali BH, Blunden G, Tanira MO, Nemmar A. Some phytochemical, pharmacological and toxicological properties of ginger (Zingiber officinale Roscoe): a review of recent research. Food Chem Toxicol. 2008;46(2):409–20.

    Article  CAS  PubMed  Google Scholar 

  117. Prasad S, Tyagi AK. Ginger and its constituents: role in prevention and treatment of gastrointestinal cancer. Gastroenterol Res Pract. 2015;2015:142979.

    Article  PubMed  PubMed Central  Google Scholar 

  118. Zick SM, Turgeon DK, Vareed SK, Ruffin MT, Litzinger AJ, Wright BD, Alrawi S, Normolle DP, Djuric Z, Brenner DE. Phase II study of the effects of ginger root extract on eicosanoids in colon mucosa in people at normal risk for colorectal cancer. Cancer Prev Res. 2011;4(11):1929–37.

    Article  Google Scholar 

  119. van Tilburg MA, Palsson OS, Levy RL, Feld AD, Turner MJ, Drossman DA, Whitehead WE. Complementary and alternative medicine use and cost in functional bowel disorders: a six month prospective study in a large HMO. BMC Complement Altern Med. 2008;8(1):1–7.

    CAS  Google Scholar 

  120. Esmaillzadeh A, Keshteli AH, Hajishafiee M, Feizi A, Feinle-Bisset C, Adibi P. Consumption of spicy foods and the prevalence of irritable bowel syndrome. World J Gastroenterol: WJG. 2013;19(38):6465.

    Article  PubMed  PubMed Central  Google Scholar 

  121. van Tilburg MA, Palsson OS, Ringel Y, Whitehead WE. Is ginger effective for the treatment of irritable bowel syndrome? A double blind randomized controlled pilot trial. Complement Ther Med. 2014;22(1):17–20.

    Article  PubMed  Google Scholar 

  122. Attari VE, Somi MH, Jafarabadi MA, Ostadrahimi A, Moaddab SY, Lotfi N. The gastro-protective effect of ginger (Zingiber officinale Roscoe) in helicobacter pylori positive functional dyspepsia. Adv Pharm Bull. 2019;9(2):321.

    Article  CAS  Google Scholar 

  123. Micklefield GH, Redeker Y, Meister V, Jung O, Greving I, May B. Effects of ginger on gastroduodenal motility. Int J Clin Pharmacol Ther. 1999;37(7):341–6.

    CAS  PubMed  Google Scholar 

  124. Hu ML, Rayner CK, Wu KL, Chuah SK, Tai WC, Chou YP, Chiu YC, Chiu KW, Hu TH. Effect of ginger on gastric motility and symptoms of functional dyspepsia. World J Gastroenterol: WJG. 2011;17(1):105.

    Article  PubMed  PubMed Central  Google Scholar 

  125. Wu KL, Rayner CK, Chuah SK, Changchien CS, Lu SN, Chiu YC, Chiu KW, Lee CM. Effects of ginger on gastric emptying and motility in healthy humans. Eur J Gastroenterol Hepatol. 2008;20(5):436–40.

    Article  PubMed  Google Scholar 

  126. Khayyal MT, Wadie W, El-Haleim EAA, Ahmed KA, Kelber O, Ammar RM, Abdel-Aziz H. STW 5 is effective against nonsteroidal anti-inflammatory drugs induced gastro-duodenal lesions in rats. World J Gastroenterol. 2019;25(39):5926.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  127. Malfertheiner P. STW 5 (Iberogast) therapy in gastrointestinal functional disorders. Dig Dis. 2017;35(S1):25–9.

    Article  PubMed  Google Scholar 

  128. Von Arnim U, Peitz U, Vinson B, Gundermann KJ, Malfertheiner P. STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study. Am J Gastroenterol. 2007;102(6):1268–75.

    Article  CAS  Google Scholar 

  129. Grundmann O, Yoon SL. Complementary and alternative medicines in irritable bowel syndrome: an integrative view. World J Gastroenterol: WJG. 2014;20(2):346.

    Article  PubMed  PubMed Central  Google Scholar 

  130. Rösch W, Vinson B, Sassin I. A randomised clinical trial comparing the efficacy of a herbal preparation STW 5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia. Z Gastroenterol. 2002;40(06):401–8.

    Article  PubMed  Google Scholar 

  131. Gundermann KJ, Godehardt E, Ulbrich M. Efficacy of a herbal preparation in patients with functional dyspepsia: a meta-analysis of double-blind, randomized, clinical trials. Adv Ther. 2003;20(1):43–9.

    Article  PubMed  Google Scholar 

  132. Vinson BR, Radke M. The herbal preparation STW 5 for the treatment of functional gastrointestinal diseases in children aged 3-14 years–a prospective non interventional study. Gastroenterology. 2011;140(5):S-102.

    Article  Google Scholar 

  133. Pilichiewicz AN, Horowitz M, Russo A, Maddox AF, Jones KL, Schemann M, Holtmann G, Feinle-Bisset C. Effects of Iberogast® on proximal gastric volume, antropyloroduodenal motility and gastric emptying in healthy men. Am J Gastroenterol. 2007;102(6):1276–83.

    Article  CAS  PubMed  Google Scholar 

  134. Lapina TL, Trukhmanov AS. Herbal preparation STW 5 for functional gastrointestinal disorders: clinical experience in everyday practice. Dig Dis. 2017;35(S1):30–5.

    Article  PubMed  Google Scholar 

  135. Allescher HD, Abdel-Aziz H. Mechanism of action of STW 5 in functional dyspepsia and IBS: the origin of multi-target. Dig Dis. 2017;35(S1):18–24.

    Article  PubMed  Google Scholar 

  136. Peterson CT, Sharma V, Uchitel S, Denniston K, Chopra D, Mills PJ, Peterson SN. Prebiotic potential of herbal medicines used in digestive health and disease. J Altern Complement Med. 2018;24(7):656–65.

    Article  PubMed  PubMed Central  Google Scholar 

  137. Cooke WM, Baron JH. Metabolic studies of deglycyrrhizinised liquorice in two patients with gastric ulcer. Digestion. 1971;4(5):264–8.

    Article  CAS  PubMed  Google Scholar 

  138. Isbrucker RA, Burdock GA. Risk and safety assessment on the consumption of Licorice root (Glycyrrhiza sp.), its extract and powder as a food ingredient, with emphasis on the pharmacology and toxicology of glycyrrhizin. Regul Toxicol Pharmacol. 2006;46(3):167–92.

    Article  CAS  PubMed  Google Scholar 

  139. Yoon JY, Cha JM, Hong SS, Kim HK, Kwak MS, Jeon JW, Shin HP. Fermented milk containing Lactobacillus paracasei and Glycyrrhiza glabra has a beneficial effect in patients with Helicobacter pylori infection: A randomized, double-blind, placebo-controlled study. Medicine. 2019;98(35):e16601.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  140. Kwon HJ, Kim HH, Ryu YB, Kim JH, Jeong HJ, Lee SW, Chang JS, Cho KO, Rho MC, Park SJ, Lee WS. In vitro anti-rotavirus activity of polyphenol compounds isolated from the roots of Glycyrrhiza uralensis. Bioorg Med Chem. 2010;18(21):7668–74.

    Article  CAS  PubMed  Google Scholar 

  141. Knipping K, Garssen J, van’t Land, B. An evaluation of the inhibitory effects against rotavirus infection of edible plant extracts. Virol J. 2012;9(1):137.

    Article  PubMed  PubMed Central  Google Scholar 

  142. Nugroho AE, Wijayanti A, Mutmainah M, Susilowati R, Rahmawati N. Gastroprotective effect of combination of hot water extracts of Licorice (Glycyrrhiza glabra), Pulasari Stem Bark (Alyxia reinwardtii), and Sembung Leaf (Blumea balsamifera) against aspirin-induced gastric ulcer model rats. J Evid Based Complementary Altern Med. 2016;21(4):NP77-NP84.

    Article  CAS  Google Scholar 

  143. Aly AM, Al-Alousi L, Salem HA. Licorice: a possible anti-inflammatory and anti-ulcer drug. AAPS PharmSciTech. 2005;6(1):E74–82.

    Article  PubMed  PubMed Central  Google Scholar 

  144. Sadra A, Kweon HS, Huh SO, Cho J. Gastroprotective and gastric motility benefits of AD-lico/Healthy Gut™ Glycyrrhiza inflata extract. Animal Cells Syst. 2017;21(4):255–62.

    Article  Google Scholar 

  145. Li Y, Liu T, Yan C, Xie R, Guo Z, Wang S, Zhang Y, Li Z, Wang B, Cao H. Diammonium glycyrrhizinate protects against nonalcoholic fatty liver disease in mice through modulation of gut microbiota and restoration of intestinal barrier. Mol Pharm. 2018;15(9):3860–70.

    Article  CAS  PubMed  Google Scholar 

  146. Dulbecco P, Savarino V. Therapeutic potential of curcumin in digestive diseases. World J Gastroenterol: WJG. 2013;19(48):9256.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  147. Ng QX, Soh AYS, Loke W, Venkatanarayanan N, Lim DY, Yeo WS. A meta-analysis of the clinical use of curcumin for irritable bowel syndrome (IBS). J Clin Med. 2018;7(10):298.

    Article  CAS  PubMed Central  Google Scholar 

  148. Lopresti AL. The problem of curcumin and its bioavailability: could its gastrointestinal influence contribute to its overall health-enhancing effects? Adv Nutr. 2018;9(1):41–50.

    Article  PubMed  PubMed Central  Google Scholar 

  149. Sarkar A, De R, Mukhopadhyay AK. Curcumin as a potential therapeutic candidate for Helicobacter pylori associated diseases. World J Gastroenterol. 2016;22(9):2736.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  150. Burge K, Gunasekaran A, Eckert J, Chaaban H. Curcumin and intestinal inflammatory diseases: molecular mechanisms of protection. Int J Mol Sci. 2019;20(8):1912.

    Article  CAS  PubMed Central  Google Scholar 

  151. Liu Z, Huang P, Law S, Tian H, Leung W, Xu C. Preventive effect of curcumin against chemotherapy-induced side-effects. Front Pharmacol. 2018;9:1374.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  152. Kozuch PL, Hanauer SB. Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol: WJG. 2008;14(3):354.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  153. Holt PR, Katz S, Kirshoff R. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci. 2005;50(11):2191–3.

    Article  PubMed  Google Scholar 

  154. Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A, Tsujikawa T, Fujiyama Y, Mitsuyama K, Sata M, Yamada M. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2006;4(12):1502–6.

    Article  CAS  PubMed  Google Scholar 

  155. Grammatikopoulou MG, Gkiouras K, Theodoridis X, Asteriou E, Forbes A, Bogdanos DP. Oral adjuvant curcumin therapy for attaining clinical remission in ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials. Nutrients. 2018;10(11):1737.

    Article  PubMed Central  CAS  Google Scholar 

  156. Zheng T, Wang X, Chen Z, He A, Zheng Z, Liu G. Efficacy of adjuvant curcumin therapy in ulcerative colitis: A metaanalysis of randomized controlled trials. Journal of gastroenterology and hepatology. 2020;35(5):722–9.

    Google Scholar 

  157. Bommelaer G, Laharie D, Nancey S, Hebuterne X, Roblin X, Nachury M, Peyrin-Biroulet L, Fumery M, Richard D, Pereira B, Goutte M. Oral curcumin no more effective than placebo in preventing recurrence of crohn’s disease after surgery in a randomized controlled trial. Clin Gastroenterol Hepatol. 2019;18(7):1553–60.

    Google Scholar 

  158. Park J, Conteas CN. Anti-carcinogenic properties of curcumin on colorectal cancer. World J Gastrointest Oncol. 2010;2(4):169.

    Article  PubMed  PubMed Central  Google Scholar 

  159. CruzCorrea M, Hylind LM, Marrero JH, Zahurak ML, Murray-Stewart T, Casero RA Jr, Montgomery EA, Iacobuzio-Donahue C, Brosens LA, Offerhaus GJ, Umar A. Efficacy and safety of curcumin in treatment of intestinal adenomas in patients with familial adenomatous polyposis. Gastroenterology. 2018;155(3):668–73.

    Article  CAS  Google Scholar 

  160. Cruz-Correa M, Shoskes DA, Sanchez P, Zhao R, Hylind LM, Wexner SD, Giardiello FM. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol. 2006;4(8):1035–8.

    Article  CAS  PubMed  Google Scholar 

  161. Mansour-Ghanaei F, Pourmasoumi M, Hadi A, Joukar F. Efficacy of curcumin/turmeric on liver enzymes in patients with non-alcoholic fatty liver disease: a systematic review of randomized controlled trials. Integr Med Res. 2019;8(1):57–61.

    Article  PubMed  Google Scholar 

  162. Rajasekaran SA. Therapeutic potential of curcumin in gastrointestinal diseases. World J Gastrointest Pathophysiol. 2011;2(1):1.

    Article  PubMed  PubMed Central  Google Scholar 

  163. Nouri-Vaskeh M, Afshan H, Mahdavi AM, Alizadeh L, Fan X, Zarei M. Curcumin ameliorates health-related quality of life in patients with liver cirrhosis: A randomized, double-blind placebo-controlled trial. Complement Ther Med. 2020;49:102351.

    Article  PubMed  Google Scholar 

  164. Miraj S, Alesaeidi S. A systematic review study of therapeutic effects of Matricaria recuitta chamomile (chamomile). Electron Physician. 2016;8(9):3024.

    Article  PubMed  PubMed Central  Google Scholar 

  165. Madisch A, Holtmann G, Plein K, Hotz J. Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial. Aliment Pharmacol Ther. 2004;19(3):271–9.

    Article  CAS  PubMed  Google Scholar 

  166. Khan I, Samson SE, Grover AK. Antioxidant supplements and gastrointestinal diseases: a critical appraisal. Med Princ Pract. 2017;26(3):201–17.

    Article  PubMed  PubMed Central  Google Scholar 

  167. Wegener T, Heimueller E. Treatment of mild gastrointestinal disorders with a herbal combination: results of a non-interventional study with gastritol® liquid. Phytother Res. 2016;30(1):72–7.

    Article  CAS  PubMed  Google Scholar 

  168. Vissiennon C, Hammoud D, Rodewald S, Fester K, Goos KH, Nieber K, Arnhold J. Chamomile flower, myrrh, and coffee charcoal, components of a traditional herbal medicinal product, diminish proinflammatory activation in human macrophages. Planta Med. 2017;83(10):846–54.

    Article  CAS  PubMed  Google Scholar 

  169. Albrecht U, Müller V, Schneider B, Stange R. Efficacy and safety of a herbal medicinal product containing myrrh, chamomile and coffee charcoal for the treatment of gastrointestinal disorders: a non-interventional study. BMJ Open Gastroenterol. 2014;1(1):e000015.

    Article  PubMed  Google Scholar 

  170. Langhorst J, Varnhagen I, Schneider SB, Albrecht U, Rueffer A, Stange R, Michalsen A, Dobos GJ. Randomised clinical trial: a herbal preparation of myrrh, chamomile and coffee charcoal compared with mesalazine in maintaining remission in ulcerative colitis–a double-blind, double-dummy study. Aliment Pharmacol Ther. 2013;38(5):490–500.

    Article  CAS  PubMed  Google Scholar 

  171. Duggan C, Gannon J, Walker WA. Protective nutrients and functional foods for the gastrointestinal tract. Am J Clin Nutr. 2002;75(5):789–808.

    Article  CAS  PubMed  Google Scholar 

  172. Limketkai BN, Wolf A, Parian AM. Nutritional interventions in the patient with inflammatory bowel disease. Gastroenterol Clin North Am. 2018;47(1):155–77.

    Article  PubMed  Google Scholar 

  173. Burke DJ, Alverdy JC, Aoys E, Moss GS. Glutamine-supplemented total parenteral nutrition improves gut immune function. Arch Surg. 1989;124(12):1396–9.

    Article  CAS  PubMed  Google Scholar 

  174. Byrne TA, Persinger RL, Young LS, Ziegler TR, Wilmore DW. A new treatment for patients with short-bowel syndrome. Growth hormone, glutamine, and a modified diet. Ann Surg. 1995;222(3):243.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  175. Klimberg VS, Souba WW, Dolson DJ, Salloum RM, Hautamaki RD, Plumley DA, Mendenhall WM, Bova FJ, Khan SR, Hackett RL, Bland KI. Prophylactic glutamine protects the intestinal mucosa from radiation injury. Cancer. 1990;66(1):62–8.

    Article  CAS  PubMed  Google Scholar 

  176. Takechi H, Mawatari K, Harada N, Nakaya Y, Asakura M, Aihara M, Takizawa H, Goto M, Nishino T, Minato T, Furukita Y. Glutamine protects the small intestinal mucosa in anticancer drug-induced rat enteritis model. J Med Invest. 2014;61(1.2):59–64.

    Article  PubMed  Google Scholar 

  177. Vidal-Casariego A, Calleja-Fernández A, de Urbina-González JJO, Cano-Rodríguez I, Cordido F, Ballesteros-Pomar MD. Efficacy of glutamine in the prevention of acute radiation enteritis: a randomized controlled trial. J Parenter Enteral Nutr. 2014;38(2):205–13.

    Article  CAS  Google Scholar 

  178. Goh J, O'morain, C.A. Nutrition and adult inflammatory bowel disease. Aliment Pharmacol Ther. 2003;17(3):307–20.

    Article  CAS  PubMed  Google Scholar 

  179. Sido B, Seel C, Hochlehnert A, Breitkreutz R, Dröge W. Low intestinal glutamine level and low glutaminase activity in Crohn’s disease: a rational for glutamine supplementation? Dig Dis Sci. 2006;51(12):2170–9.

    Article  CAS  PubMed  Google Scholar 

  180. Zhou Q, Souba WW, Croce CM, Verne GN. MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome. Gut. 2010;59(6):775–84.

    Article  CAS  PubMed  Google Scholar 

  181. Coëffier M, Déchelotte P, Ducrotté P. Intestinal permeability in patients with diarrhea-predominant irritable bowel syndrome: is there a place for glutamine supplementation? Gastroenterology. 2015;148(5):1079–80.

    Article  PubMed  CAS  Google Scholar 

  182. Zhou Q, Verne ML, Fields JZ, Lefante JJ, Basra S, Salameh H, Verne GN. Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome. Gut. 2019;68(6):996–1002.

    Article  CAS  PubMed  Google Scholar 

  183. Ford AC, Gibson PR. Efficacy of glutamine in postinfection IBS. Gut. 2019;68(10):1905–6.

    Article  CAS  PubMed  Google Scholar 

  184. Heymsfield SB, Allison DB, Vasselli JR, Pietrobelli A, Greenfield D, Nunez C. Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent: a randomized controlled trial. JAMA. 1998;280(18):1596–600.

    Article  CAS  PubMed  Google Scholar 

  185. Pittler MH, Ernst E. Dietary supplements for body-weight reduction: a systematic review. Am J Clin Nutr. 2004;79(4):529–36.

    Article  CAS  PubMed  Google Scholar 

  186. Mahendran P, Vanisree AJ, Shyamala Devi CS. The antiulcer activity of Garcinia cambogia extract against indomethacin-induced gastric ulcer in rats. Phytother Res. 2002;16(1):80–3.

    Article  CAS  PubMed  Google Scholar 

  187. Boakye PA, Stenkamp-Strahm C, Bhattarai Y, Heckman MD, Brierley SM, Pasilis SP, Balemba OB. 5-HT3 and 5-HT4 receptors contribute to the anti-motility effects of Garcinia buchananii bark extract in the guinea-pig distal colon. Neurogastroenterol Motil. 2012;24(1):e27–40.

    Article  CAS  PubMed  Google Scholar 

  188. Udia PM, Braide VB, Owu DU. Antispasmodic and spasmolytic effects of methanolic extract from seeds of Garcinia kola on isolated rat small intestine. Niger J Physiol Sci. 2009;24(2):111.

    CAS  PubMed  Google Scholar 

  189. Lunsford KE, Bodzin AS, Reino DC, Wang HL, Busuttil RW. Dangerous dietary supplements: Garcinia cambogia-associated hepatic failure requiring transplantation. World J Gastroenterol. 2016;22(45):10071.

    Article  PubMed  PubMed Central  Google Scholar 

  190. Sharma A, Akagi E, Njie A, Goyal S, Arsene C, Krishnamoorthy G, Ehrinpreis M. Acute hepatitis due to Garcinia cambogia extract, an herbal weight loss supplement. Case Rep Gastrointest Med. 2018;2018:9606171.

    PubMed  PubMed Central  Google Scholar 

  191. Yousaf MN, Chaudhary FS, Hodanazari SM, Sittambalam CD. Hepatotoxicity associated with Garcinia cambogia: A case report. World J Hepatol. 2019;11(11):735.

    Article  PubMed  PubMed Central  Google Scholar 

  192. Kothadia JP, Kaminski M, Samant H, Olivera-Martinez M. Hepatotoxicity associated with use of the weight loss supplement Garcinia cambogia: a case report and review of the literature. Case Reports Hepatol. 2018;2018:6483605.

    Article  PubMed  PubMed Central  Google Scholar 

  193. Mhurchu CCN, Dunshea-Mooij CA, Bennett DA, Rodgers AA. Chitosan for overweight or obesity. Cochrane Database Syst Rev. 2005;3:CD003892.

    Google Scholar 

  194. Moraru C, Mincea MM, Frandes M, Timar B, Ostafe V. A meta-analysis on randomised controlled clinical trials evaluating the effect of the dietary supplement chitosan on weight loss, lipid parameters and blood pressure. Medicina. 2018;54(6):109.

    Article  PubMed Central  Google Scholar 

  195. Qian M, Lyu Q, Liu Y, Hu H, Wang S, Pan C, Duan X, Gao Y, Qi LW, Liu W, Wang L. Chitosan Oligosaccharide Ameliorates Nonalcoholic Fatty Liver Disease (NAFLD) in Diet-Induced Obese Mice. Mar Drugs. 2019;17(7):391.

    Article  CAS  PubMed Central  Google Scholar 

  196. Loening-Baucke V, Miele E, Staiano A. Fiber (glucomannan) is beneficial in the treatment of childhood constipation. Pediatrics. 2004;113(3):e259–64.

    Article  PubMed  Google Scholar 

  197. Sood N, Baker WL, Coleman CI. Effect of glucomannan on plasma lipid and glucose concentrations, body weight, and blood pressure: systematic review and meta-analysis. Am J Clin Nutr. 2008;88(4):1167–75.

    Article  CAS  PubMed  Google Scholar 

  198. Onakpoya I, Posadzki P, Ernst E. The efficacy of glucomannan supplementation in overweight and obesity: a systematic review and meta-analysis of randomized clinical trials. J Am Coll Nutr. 2014;33(1):70–8.

    Article  CAS  PubMed  Google Scholar 

  199. Keithley JK, Swanson B, Mikolaitis SL, DeMeo M, Zeller JM, Fogg L, Adamji J. Safety and efficacy of glucomannan for weight loss in overweight and moderately obese adults. J Obes. 2013;2013:610908.

    Article  PubMed  PubMed Central  Google Scholar 

  200. Zalewski BM, Szajewska H. No effect of glucomannan on body weight reduction in children and adolescents with overweight and obesity: a randomized controlled trial. J Pediatr. 2019;211:85–91.

    Article  CAS  PubMed  Google Scholar 

  201. Horvath A, Dziechciarz P, Szajewska H. Glucomannan for abdominal pain-related functional gastrointestinal disorders in children: a randomized trial. World J Gastroenterol: WJG. 2013;19(20):3062.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  202. Chmielewska A, Horvath A, Dziechciarz P, Szajewska H. Glucomannan is not effective for the treatment of functional constipation in children: a double-blind, placebo-controlled, randomized trial. Clin Nutr. 2011;30(4):462–8.

    Article  CAS  PubMed  Google Scholar 

  203. Han Y, Zhang L, Liu XQ, Zhao ZJ, Lv LX. Effect of glucomannan on functional constipation in children: a systematic review and meta-analysis of randomised controlled trials. Asia Pac J Clin Nutr. 2017;26(3):471.

    PubMed  Google Scholar 

  204. Jurgens TM, Whelan AM, Killian L, Doucette S, Kirk S, Foy E. Green tea for weight loss and weight maintenance in overweight or obese adults. Cochrane Database Syst Rev. 2012;12(12):CD008650.

    PubMed  Google Scholar 

  205. Masterjohn C, Bruno RS. Therapeutic potential of green tea in nonalcoholic fatty liver disease. Nutr Rev. 2012;70(1):41–56.

    Article  PubMed  Google Scholar 

  206. Chen IJ, Liu CY, Chiu JP, Hsu CH. Therapeutic effect of high-dose green tea extract on weight reduction: A randomized, double-blind, placebo-controlled clinical trial. Clin Nutr. 2016;35(3):592–9.

    Article  CAS  PubMed  Google Scholar 

  207. Hoofnagle JH, Wright EC. Weight loss from green tea extracts. Clin Nutr. 2016;35(1):238.

    Article  PubMed  Google Scholar 

  208. Gilardini L, Pasqualinotto L, Di Pierro F, Risso P, Invitti C. Effects of Greenselect Phytosome® on weight maintenance after weight loss in obese women: a randomized placebo-controlled study. BMC Complement Altern Med. 2016;16(1):233.

    Article  PubMed  PubMed Central  Google Scholar 

  209. Hu J, Webster D, Cao J, Shao A. The safety of green tea and green tea extract consumption in adults–results of a systematic review. Regul Toxicol Pharmacol. 2018;95:412–33.

    Article  CAS  PubMed  Google Scholar 

  210. Patel SS, Beer S, Kearney DL, Phillips G, Carter BA. Green tea extract: a potential cause of acute liver failure. World J Gastroenterol: WJG. 2013;19(31):5174.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  211. Molinari M, Watt KD, Kruszyna T, Nelson R, Walsh M, Huang WY, Nashan B, Peltekian K. Acute liver failure induced by green tea extracts: case report and review of the literature. Liver Transpl. 2006;12(12):1892–5.

    Article  PubMed  Google Scholar 

  212. Sarma DN, Barrett ML, Chavez ML, Gardiner P, Ko R, Mahady GB, Marles RJ, Pellicore LS, Giancaspro GI, Dog TL. Safety of green tea extracts. Drug Saf. 2008;31(6):469–84.

    Article  PubMed  Google Scholar 

  213. Food and Drug Administration (FDA). Food composition, standards, labeling and economics: Chapter 21, Compliance Program 7321.002. Compliance Program Guidance Manual. 2008.

    Google Scholar 

  214. US Food and Drug Administration (FDA). Guidance for industry: frequently asked questions about medical foods; second edition. 2007. Retrieved from https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-frequently-asked-questions-about-medical-foods-second-edition. Updated 12 Dec 2016.

  215. Levine A, Wine E, Assa A, Boneh RS, Shaoul R, Kor i M, Cohen S, Peleg S, Shamaly H, On A, Millman P. Crohn’s disease exclusion diet plus partial enteral nutrition induces sustained remission in a randomized controlled trial. Gastroenterology. 2019;157(2):440–50.

    Article  PubMed  Google Scholar 

  216. Narula N, Dhillon A, Zhang D, Sherlock ME, Tondeur M, Zachos M. Enteral nutritional therapy for induction of remission in Crohn’s disease. Cochrane Database of Systematic Reviews. 2018(4).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology and Liver Disease, New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY, USA

    Pratima Dibba, Megha Kothari & Irwin Grosman

Authors
  1. Pratima Dibba
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Megha Kothari
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Irwin Grosman
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Gastroenterology, Weill Cornell Medical Center, New York, NY, USA

    Carolyn Newberry

  2. Gastroenterology, Obesity Medicine Nutrition and Bariatric Endoscopist Gut Theory Total Digestive Care, George Washington University Hospital, Washington, DC, USA

    Janese Laster

  3. GI Nutrition, Celiac Disease and Obesity Program, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA

    Octavia Pickett-Blakely

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Dibba, P., Kothari, M., Grosman, I. (2022). Prebiotics, Probiotics, and Dietary Supplements. In: Newberry, C., Laster, J., Pickett-Blakely, O. (eds) Nutrition, Weight, and Digestive Health. Springer, Cham. https://doi.org/10.1007/978-3-030-94953-2_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-94953-2_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-94952-5

  • Online ISBN: 978-3-030-94953-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation